Are you a physician?
Agenus will be attending the ASCO GI Congress 2025 in San Francisco, January 22 - 26.
Let’s meet to discuss the future of immuno-oncology.

For SAEs, regardless of attribution, the investigator must notify Agenus immediately (i.e., ≤24 hours after becoming aware) via e-mail on an SAE report form provided by Agenus and later send the MedWatch FDA F3500A used for submission to FDA by fax or e-mail:

By electronic media (Adverse.Events@Agenusbio.com)

Or

Paper (Fax: +1-781-674-4261)

The Investigator’s assessment of an AEs relationship to the study medication will be included on the SAE report submitted to drug manufacturer. For overdoses associated with a SAE, standard reporting timelines apply.

Reporting procedures and timelines are the same for any new information on a previously reported SAE or pregnancy (= follow-up).